Catalog No.
Product Name
Application
Product Information
Citations
-
Lysosomal cysteine protease
Cathepsin H, human liver, is a lysosomal cysteine protease that functions as both an aminopeptidase and an endopeptidase. This enzyme is essential for the catabolism of proteins within the lysosomal system. It plays a significant role in regulating tumor cell behavior and is implicated in the pathological processes of various brain diseases, making it valuable for research in cancer biology and neurodegenerative disorders. -
PCSK9/HMG-CoAR Inhibitor
Dim16 is a dual inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) and HMG-CoA reductase (HMG-CoAR), demonstrating an IC50 value of 19 nM for PCSK9. It effectively inhibits the binding of PCSK9 to the LDL receptor (LDLR) with an IC50 of 0.8 nM. This compound is noted for its role in enhancing LDL uptake in HepG2 cells, making it valuable for research in cholesterol metabolism and cardiovascular diseases. -
Ser/Thr Protease
RWJ-58643 hydrochloride is a selective inhibitor of serine/threonine proteases, specifically targeting β-trypsin. It has demonstrated efficacy in reducing nasal allergy symptoms, eosinophil infiltration, and interleukin-5 (IL-5) levels at low doses, highlighting its potential for modulating allergic inflammation. Notably, administration at higher doses may lead to late eosinophilia and increased IL-5 levels. RWJ-58643 hydrochloride is valuable for research focused on understanding and managing allergic reactions through protease inhibition. -
Ser/Thr Protease Inhibitor
RWJ-58643 is a selective Ser/Thr protease inhibitor that primarily targets β-trypsin, modulating allergic inflammation pathways. This compound has demonstrated significant efficacy in reducing nasal allergy symptoms, eosinophil infiltration, and IL-5 levels at low doses, while high doses have been associated with late eosinophilia and increased IL-5 levels. RWJ-58643 functions by inhibiting the release of β-trypsin from mast cells, making it a valuable tool for research into allergic responses and related inflammatory conditions. -
Ser/Thr Protease
MDK0734 is a selective inhibitor targeting serine/threonine proteases, specifically inhibiting feline hepsin B endopeptidase and exopeptidase activities. It has been shown to effectively reduce tumor cell invasion in vitro, significantly impairing the invasive behavior of MCF-10A neoT cells. MDK0734 opens new avenues for developing clinically relevant compounds aimed at mitigating the damaging effects of feline hepsin B in cancer progression. -
AhR Ligand
β-Naphthoflavone-CH2-Br is a ligand for the arylhydrocarbon receptor (AhR), involved in regulating various biological processes, including xenobiotic metabolism. This compound serves as a key intermediate for synthesizing the PROTAC β-NF-JQ1, facilitating targeted protein degradation research. Its role in modulating AhR activity makes it valuable for studies in toxicology, pharmacology, and cancer research. -
MAO-B Inhibitor
Milacemide is an orally active inhibitor of monoamine oxidase B (MAO-B), classified as a glycinamide derivative. This compound demonstrates anticonvulsant effects by modulating the levels of neurotransmitters; it decreases dihydroxyphenylacetic acid and homovanilic acid while enhancing dopamine and serotonin levels in the caudate nucleus. Milacemide holds potential for research applications related to neurodegenerative disorders, particularly Alzheimer's disease. -
hMAO-B Inhibitor
hMAO-B-IN-7 is a potent inhibitor of human monoamine oxidase-B (hMAO-B) with an IC50 value of 0.79±0.05 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for studies related to neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its ability to inhibit hMAO-B positions it as a valuable tool for exploring therapeutic approaches in these conditions. -
MAO-B Inhibitor
MAO-B-IN-39 is a selective monoamine oxidase B (MAO-B) inhibitor that demonstrates an IC50 of 3.61 μM. It exhibits potent induction of NRF2, contributing to its significant anti-inflammatory and neuroprotective effects in oxidative stress-related in vitro models. Additionally, MAO-B-IN-39 has shown high liver microsomal stability and favorable pharmacokinetics in murine studies, indicating its potential utility in Parkinson's disease research. -
MAO-B Inhibitor
MAO-B-IN-21 is a potent inhibitor of monoamine oxidase B (MAO-B) that also demonstrates antioxidant properties. This compound exhibits anti-amyloid-beta (Aβ) aggregation activity, metal-ion chelation, and anti-neuroinflammatory effects, specifically targeting nitric oxide and TNF-α pathways. Additionally, MAO-B-IN-21 is neuroprotective and can cross the blood-brain barrier. Its efficacy in enhancing memory and cognitive function has been established in a mouse model of Alzheimer’s disease induced by Aβ1-42. -
Monoamine Oxidase A Inhibitor
Rubrofusarin triglucoside is a glycoside compound that serves as an inhibitor of human monoamine oxidase A (hMAO-A), demonstrating an IC50 value of 85.5 μM. This compound is isolated from the seeds of Cassia obtusifolia Linn and plays a significant role in neurochemical studies related to mood regulation and depression. Its inhibition of hMAO-A makes it a valuable reagent for research into neuropharmacology and the therapeutic potential of monoamine oxidase inhibitors. -
MAO-B Inhibitor
MAO-B-IN-55 is a reversible competitive inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 of 2.9 nM and a remarkable 2750-fold selectivity for MAO-B over MAO-A. This compound is valuable for studying the biochemical pathways involved in Parkinson's disease, making it a significant tool for both in vitro and in vivo research applications focused on neurodegenerative disorders. -
MAO-B Inhibitor
MAO-B-IN-37 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 270 nM. This compound demonstrates favorable metabolic stability in mouse microsomes, along with strong binding affinity to human serum albumin. It is valuable for research applications focused on neurological disorders and oxidative stress, where modulation of MAO-B activity may provide therapeutic insights. -
MAO Inhibitor
SL-251131 is a reversible non-specific monoamine oxidase (MAO) inhibitor, targeting both MAO-A and MAO-B enzymes. By inhibiting these enzymes, SL-251131 temporarily increases the levels of neurotransmitters such as dopamine, making it a valuable tool for studying neurodegenerative disorders, particularly Parkinson's disease. Its application in research facilitates a deeper understanding of the biochemical pathways involved in dopaminergic signaling and related pathologies. -
MAO-B Inhibitor
Homopterocarpin is an isoflavonoid that serves as a competitive reversible inhibitor of human monoamine oxidase B (hMAO-B), with an IC50 value of 0.72 μM and a Ki of 0.21 μM. This compound demonstrates significant hepatoprotective and antioxidant properties, making it a valuable tool in studies related to liver injury and oxidative stress. Its selective inhibition of hMAO-B positions Homopterocarpin as an important reagent for exploring neurodegenerative conditions and biochemical pathways associated with cellular stress responses. -
MAO-A Inhibitor
(±)-Amiflamine serves as a potent inhibitor of monoamine oxidase-A (MAO-A), exhibiting a pIC50 value of 5.57. This compound is significant for investigating the modulation of neurotransmitter levels, making it valuable in studies related to mood disorders and neurodegenerative diseases. Its ability to inhibit MAO-A highlights its potential application in the research of therapeutic agents targeting depression and anxiety disorders. -
MAO-B Inhibitor
MAO-B-IN-13 is a potent reversible inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 10 nM, demonstrating strong blood-brain barrier penetration. This compound exhibits neuroprotective and antioxidant properties, making it a valuable tool for research focused on neurodegenerative disorders, particularly Parkinson's disease. -
MAO-A Inhibitor
Cimoxatone is a reversible and selective inhibitor of monoamine oxidase A (MAO-A), demonstrating oral bioactivity. This compound enhances the anorectic effects of serotonin, making it pertinent for studies related to appetite regulation and mood disorders. Its mechanism of action facilitates increased serotonin levels, contributing to research in neuropharmacology and potential therapeutic applications in depression and obesity. -
MAO Inhibitor
Benmoxin is a potent monoamine oxidase (MAO) inhibitor that plays a crucial role in the modulation of neurotransmitter levels. This compound is primarily utilized in depression research, offering insights into the biochemical pathways associated with mood disorders. Benmoxin serves as a valuable tool for studying the effects of MAO inhibition on neurochemical balance and potential therapeutic interventions. -
MAO-B Inhibitor
PSB-1491 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.386 nM for human MAO-B. This compound exhibits over 25,000-fold selectivity towards MAO-B compared to MAO-A, making it a valuable tool for studying neurodegenerative diseases and exploring potential therapeutic applications in disorders such as Parkinson's disease. Its high potency and selectivity make PSB-1491 an important reagent for research focused on modulating monoamine neurotransmitter levels. -
hMAO-B Inhibitor
hMAO-B-IN-4 is a selective and reversible inhibitor of human monoamine oxidase-B (hMAO-B), demonstrating an IC50 of 0.067 µM and a Ki of 0.03 µM. It exhibits less potency against hMAO-A with an IC50 value of 33.82 µM. This compound effectively penetrates the blood-brain barrier, making it a valuable tool for research into neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. -
MAO-B Inhibitor
MAO-B-IN-33 is a potent, reversible, and selective inhibitor of monoamine oxidase-B (MAO-B) with an IC50 of 0.021 μM for MAO-B and 26.805 μM for MAO-A, highlighting its selectivity. Its distinctive action is attributed to steric hindrance caused by differences in amino acid residues between MAO-A and MAO-B. This compound effectively inhibits cerebral MAO-B activity and demonstrates the ability to mitigate MPTP-induced dopaminergic neuronal loss in murine models. MAO-B-IN-33 shows promise for applications in Parkinson's disease research. -
Monoamine Oxidase Inhibitor
(+)-Cinchonaminone acts as a monoamine oxidase inhibitor, demonstrating significant activity in the modulation of neurotransmitter levels. This compound is valuable for research applications focusing on neuropharmacology, depression, and other mood disorders, where the regulation of monoamines is critical. -
hMAO-B Inhibitor
hMAO-B-IN-2 is a potent and selective inhibitor of human monoamine oxidase B (hMAO-B), exhibiting a competitive reversible mechanism with an IC50 of 4 nM. This compound is characterized by its ability to penetrate the blood-brain barrier and demonstrates low toxicity alongside significant neuroprotective effects in SH-SY5Y neuroblastoma cells. hMAO-B-IN-2 is suitable for research applications related to Alzheimer's disease and also serves as a versatile click chemistry reagent, featuring an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. -
MAO-B Inhibitor
MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B), exhibiting an IC50 value of 1.55 µM. This compound is valuable for investigating the role of MAO-B in central nervous disorders, particularly in the context of Parkinson's disease. Its use can enhance understanding of disease mechanisms and contribute to the development of therapeutic strategies targeting MAO-B. -
MAO Inhibitor
Echitovenidine is a naturally occurring alkaloid isolated from Alstonia yunnanensis, functioning as a potent monoamine oxidase (MAO) inhibitor. This compound demonstrates significant biological activity in modulating neurotransmitter levels, making it valuable for research in neuropharmacology and the exploration of mood disorders. Echitovenidine's mechanism of action can facilitate studies aimed at understanding the role of MAO in various neurological conditions. -
MAO-B Inhibitor
1-Methyl-2-undecyl-4(1H)-quinolone is a selective and irreversible inhibitor of type B monoamine oxidase (MAO-B). It exhibits potent inhibition with IC50 and Ki values of 15.3 μM and 9.91 μM, respectively, without affecting type A monoamine oxidase (MAO-A) activity. This quinolone alkaloid, derived from the fresh leaves and fruits of Evodia rutaecarpa, is valuable in research focused on neurological disorders and the modulation of neurotransmitter levels. -
MAO A/B Inhibitor
MAO-IN-3 is a reversible and competitive inhibitor of monoamine oxidase A and B, exhibiting Ki values of 0.6 μM and 0.2 μM, respectively. This compound demonstrates significant anti-proliferative effects on LN-229 glioblastoma cells, with an IC50 of 0.8 μM. MAO-IN-3 is suitable for research applications focused on cancer biology and therapeutic development targeting monoamine oxidase pathways. -
MAO-B Inhibitor
MAO-B-IN-14 is a selective monoamine oxidase-B (MAO-B) inhibitor, exhibiting an IC50 of 0.95 μM and a Ki of 0.55 μM against human MAO-B. This compound demonstrates significant potential for research applications focused on neurodegenerative disorders, particularly those involving dopaminergic pathways. Its inhibitory properties make it a valuable tool for studies exploring the role of MAO-B in neurological conditions and therapeutic interventions targeting this enzyme. -
MAO-B Inhibitor
MAO-B-IN-47 is a selective inhibitor of monoamine oxidase B (MAO-B) with a Ki of 875 nM. This compound demonstrates neuroprotective effects in SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA), showing an IC50 greater than 100 μM. MAO-B-IN-47 is valuable for research into neurological disorders, particularly Parkinson's disease, by potentially mitigating neuronal damage associated with MAO-B activity. -
hMAO-B Inhibitor
hMAO-B-IN-6 is a potent and selective inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 67.02 nM. This compound has demonstrated significant efficacy in reversing Scopolamine-induced cognitive impairment in mouse models of Alzheimer's disease. Its application in research highlights its potential for further investigations into neurodegenerative disorders and cognitive enhancement therapies. -
MAO-B Inhibitor
MAO-B-IN-22 is a potent inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 0.014 μM. This compound exhibits strong antioxidant activity and effective metal chelation capabilities, contributing to its significant neuroprotective effects. It demonstrates suitable blood-brain barrier permeability, making it a valuable reagent for research applications focused on neurodegenerative diseases and oxidative stress. -
MAO-B Inhibitor
MAO-B ligand-1 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating IC50 values of 3.83 nM against human MAO-B and 22.57 nM against human MAO-A. This compound is valuable for studying the regulation of neurotransmitters and the biochemical pathways involved in neurodegenerative diseases. MAO-B ligand-1 is suitable for applications in pharmacological research and the development of therapeutic agents targeting MAO-B related disorders. -
MAO-B Inhibitor
MAO-B-IN-11 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 1.3 μM. This compound exhibits neuroprotective activity, making it a valuable tool for research focused on neurodegenerative diseases and related therapeutic strategies. Its potency and selectivity position MAO-B-IN-11 as an important reagent for studies on the modulation of neurotransmitter metabolism. -
MAO-A And 5-HT-uptake Inhibitor
Sercloremine hydrochloride is a selective and reversible inhibitor of monoamine oxidase A (MAO-A) and serotonin (5-HT) uptake. This compound is primarily utilized in research related to depression, offering insights into the modulation of serotonin levels and its effects on mood regulation. Its dual mechanism of action makes it valuable for exploring therapeutic approaches in depressive disorders. -
MAO-B Inhibitor
MAO-B-IN-5 is a selective and orally active inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 of 0.204 µM. This compound is designed for research applications related to neurodegenerative disorders, particularly Parkinson's disease (PD). Its potent inhibition of MAO-B may contribute to the understanding of dopamine metabolism and neuroprotection in PD studies. -
MAO Inhibitor
MAO-IN-5 is a selective monoamine oxidase (MAO) inhibitor, demonstrating significant potential for modulating neurotransmitter levels. This compound exhibits promising blood-brain barrier permeability and a high gastrointestinal absorption rate, making it valuable for in vivo studies. MAO-IN-5 is primarily utilized in research addressing neurological disorders, contributing to the understanding of MAO-related pathways in various pathologies. -
MAO-B Inhibitor
MAO-B-IN-51 is a selective, orally active inhibitor of monoamine oxidase B (MAO-B) with a blood-brain barrier permeability. It demonstrates an IC50 value of 48.9 nM, indicating potent inhibition of MAO-B activity. This compound has been shown to enhance long-term memory, making it a valuable tool for research on neurodegenerative disorders and cognitive function. -
MAO-A Inhibitor
2-PAT is a reversible inhibitor of monoamine oxidase A (MAO-A) with an IC50 value of 0.721 µM, demonstrating significant biochemical activity. Additionally, it acts as an inactivator of monoamine oxidase B (MAO-B) with an IC50 of 14.6 µM. This compound is valuable for research related to Parkinson’s disease and depression, providing a useful tool for investigating the therapeutic potential of MAO inhibitors in neurological disorders. -
MAO-B Inhibitor
C175-0062 is a selective monoamine oxidase B (MAO-B) inhibitor. This compound exhibits neuroprotective properties that are significant for understanding and researching neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS). C175-0062 serves as a valuable tool in the study of pathways involved in these conditions, contributing to the development of therapeutic strategies. -
Type A MAO Inhibitor
Bazinaprine is an orally active type A monoamine oxidase (MAO) inhibitor. It exhibits significant potential in modulating neurotransmitter levels, making it a valuable tool in research related to depression. This compound may help elucidate the mechanisms underlying mood disorders and facilitate the development of novel therapeutic strategies. -
hMAO-B Inhibitor
MAO-B-IN-28 is a potent human monoamine oxidase B (hMAO-B) inhibitor with an IC50 of 1.9±0.5 nM. This compound demonstrates significant neuroprotective activity, making it a valuable tool in the study of neurodegenerative diseases. Its selective inhibition of hMAO-B may contribute to the understanding of oxidative stress and neuroinflammation in relevant research applications. -
MAO-B Inhibitor
MAO-B-IN-23 is a reversible and competitive inhibitor of monoamine oxidase B (MAO-B), with an IC50 value of 1.44 μM and a Ki of 0.51 μM. This compound is valuable for investigating the role of MAO-B in neurodegenerative diseases and can be used in studies focused on neuroprotective strategies and modulation of neurotransmitter levels. Its specific inhibition of MAO-B makes it a useful tool for research into Parkinson's disease and related disorders. -
MAOB Inhibitor
MAO-B-IN-40 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 0.493 μM for human MAO-B. This compound exhibits significant neuroprotective and antioxidant properties, making it a valuable tool in the study of neurodegenerative disorders. MAO-B-IN-40 is particularly relevant in Parkinson's disease research, where the modulation of MAO-B activity may help mitigate disease progression and improve therapeutic outcomes. -
MAO-A Inhibitor
(R)-Pirlindole mesylate is a selective and reversible inhibitor of Monoamine oxidase A (MAO-A), exhibiting an IC50 of 0.43 μM against MAO-A with minimal effect on MAO-B. This compound demonstrates notable antidepressant activity, as evidenced by a significant reduction in immobility time in the forced swim test. Additionally, (R)-Pirlindole mesylate effectively inhibits Reserpine-induced palpebral ptosis in behavioral mice models. Its properties make it a valuable tool for research into depression and related disorders. -
MAO Inhibitor
MAO-IN-4 is a potent monoamine oxidase (MAO) inhibitor, exhibiting IC50 values of 0.07 μM for MAO-A and 0.75 μM for MAO-B. This compound is valuable for research focused on neurodegenerative disorders and mood disorders, particularly depression and Parkinson’s disease (PD). Its selective inhibition of MAO enzymes provides insight into therapeutic approaches for these conditions. -
MAO-B Inhibitor
Almoxatone is a potent, orally bioavailable inhibitor of monoamine oxidase B (MAO-B). Its primary mechanism involves the selective inhibition of MAO-B enzyme activity, which plays a crucial role in the metabolism of neurotransmitters such as dopamine. Almoxatone demonstrates significant potential in research applications related to neurodegenerative disorders and mood regulation, making it a valuable tool for studying the neurological implications of monoamine metabolism. -
MAO-B Inhibitor
1-Methyl-2-nonyl-4(1H)-quinolone is a selective inhibitor of monoamine oxidase B (MAO-B). This quinolone alkaloid demonstrates significant inhibitory activity on leukotriene biosynthesis, with an IC50 value of 12.1 μM. It is a valuable tool for research in neurodegenerative diseases and inflammation-related studies. -
Monoamine Oxidase Inhibitor
MAO-B-IN-34 is a selective monoamine oxidase B (MAO-B) inhibitor that plays a crucial role in regulating the breakdown of neurotransmitters such as dopamine. By inhibiting MAO-B, this compound may enhance dopaminergic signaling, making it a valuable tool in research related to neurodegenerative diseases like Parkinson's disease. Its application extends to studying the pharmacological effects of neurotransmitter modulation in various neurological contexts. -
MAO-B Inhibitor
MAO-B-IN-17 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 5.08 μM. This compound plays a significant role in modulating monoaminergic neurotransmission and is applicable in research focused on Parkinson's disease and related neurodegenerative disorders. Its specificity for MAO-B makes it a valuable tool for studying the implications of monoamine metabolism in neurological conditions.
